

3rd pRED Oncology Award


Roche Diagnostics GmbH
pRED Innovation Center Penzberg
Nonnenwald 2
82377 Penzberg
Germany

www.roche.com

© 2015

Call for Abstracts

*“Pathophysiology of the extracellular matrix -
basic concepts and therapeutic approaches
for cancer therapy”*



Roche in Penzberg

Biotech from Science to Patients

Roche in Penzberg, just south of Munich, is one of the largest sites of the Roche Group. About 5,500 employees work in research, development and production of Diagnostics and Pharmaceuticals.

The site is one of the largest biotech centers in Europe and a powerhouse for proteins including antibodies for diagnosis and therapy

Roche pRED

Pharma Research & Early Development

The Roche Pharma Research and Early Development organization – pRED – consists of more than 2,200 scientists and clinicians with a shared vision of excellence in science, a proud heritage of healthcare innovation and a commitment to deliver new and effective medicines to patients. We translate world-class science into medical innovation through a diversity of therapeutic modalities and fully leveraging technologies and talent, both internally and externally. We deliver on individual patient needs through a deep understanding of disease biology and the implementation of Personalised Healthcare (PHC) strategies.

pRED focuses on the areas: Oncology, Immunology and Inflammation, Infectious Diseases, Neuroscience, Ophthalmology, and Rare Diseases at seven strategic sites worldwide.

The Oncology unit at the pRED Innovation Center in Penzberg, Germany, is focusing on research in the field of targeted cancer therapeutics, tumor micro-environment and cancer immuno-therapy.

Call for Abstracts

in Oncology

“Pathophysiology of the extracellular matrix - basic concepts and therapeutic approaches for cancer therapy”

Extracellular matrix (ECM) plays a pivotal role in many processes during development, tissue homeostasis and remodeling. The pathophysiology of the ECM is considered as a promising area with anticipated impact on targeted cancer drug delivery and cancer immuno-therapy.

For the 3rd pRED Oncology Award the Roche pRED Discovery Oncology unit in Penzberg invites authors to submit abstracts which describe their scientific work in the fields of basic mechanisms and the pathophysiology of the extracellular matrix.

Topics include but are not restricted to the impact of ECM on:

immune cell function, migration of immune effector cells, interstitial pressure within the tumor mass, accessibility and penetration of solid tumors by therapeutic antibodies and small molecules, metastasis formation, angiogenesis, adhesion and anoikis, tumor-specific targeting.

Qualified applicants include graduate students and post-doctoral fellows in Europe. Abstracts will be reviewed by a panel of experts from Roche and academic institutions and selected for presentation and awards on the basis of scientific merit. The ten best contributions will be elected and the authors will be invited to the Roche Penzberg campus for presentation and poster discussion on October 29 and 30, 2015. Thereafter, three winners will be selected and receive an award of 4.000 €, 2.000 € and 1.000 € respectively. The deadline for abstract submission is August 15, 2015. For submission guidelines and additional information, please visit www.roche.de/oncologyaward.

